Insights
Search Results
Client Highlights
6.17.26
Wilson Sonsini Advises Enliven Therapeutics on $460 Million Follow-On Offering
On June 15, 2026, Enliven Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, closed an upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven Therapeutics' common stock less the $0.001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven Therapeutics. The gross proceeds from the offering were approximately $460 million before deducting underwriting discounts and commissions and other offering expenses.
Client Highlights
3.27.26
Wilson Sonsini Advises Excellergy on $2 Billion Acquisition by Novartis
On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Client Highlights
3.27.26
Wilson Sonsini Advises OnKure Therapeutics on $150 Million Private Placement
On March 27, 2026, OnKure Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel precision medicines, announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proceeds of approximately $150 million. Wilson Sonsini Goodrich & Rosati advised OnKure on the transaction.
Client Highlights
12.15.25
Wilson Sonsini Advises Excellergy on $70 Million Series A
On October 13, 2025, Excellergy, a biotechnology company developing a new class of allergy therapeutics, announced its launch with a $70 million Series A financing to advance its pipeline of first-in-class allergic Effector Cell Response Inhibitors (ECRIs). Excellergy is backed by leading healthcare investors, with Samsara BioCapital serving as the Series A lead with co-investments from Red Tree Venture Capital and Decheng Capital. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Client Highlights
12.15.25
Wilson Sonsini Advises Tenaya Therapeutics on Pricing of Public Offering
On December 11, 2025, Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop, and deliver potentially curative therapies that address the underlying causes of heart disease, announced the pricing of its underwritten public offering of 50,000,000 total units for gross proceeds of $60 million prior to deducting underwriting discounts and commissions and offering expenses. Wilson Sonsini Goodrich & Rosati advised Tenaya on the transaction.
Client Highlights
12.12.25
Wilson Sonsini Advises Denali Therapeutics on $200 Million Public Offering
On December 10, 2025, Denali Therapeutics, a biopharmaceutical company focused on therapies for neurodegenerative and lysosomal storage diseases, announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,285,714 shares of common stock at a price of $17.49 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.01 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Denali Therapeutics. Denali Therapeutics expects to receive total gross proceeds of approximately $200 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters’ option to purchase additional shares. Wilson Sonsini Goodrich & Rosati advised Denali Therapeutics on the transaction.
Client Highlights
6.18.25
Firm Advises Enliven Therapeutics on $230 Million Public Offering
On June 16, 2025, Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, announced the close of its underwritten public offering of 9,920,987 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,526,250 additional shares of its common stock, at a price to the public of $19.66 per share and pre-funded warrants to purchase 1,780,263 shares of its common stock at a price to the public of $19.659 per pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven. The gross proceeds from the offering were approximately $230 million before deducting underwriting discounts and commissions and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Enliven on the offering.
Client Highlights
4.16.25
Wilson Sonsini Advises Glycomine on $115 Million Series C
On April 16, 2025, Glycomine, a biotechnology company focused on developing transformative new therapies for orphan diseases, announced a $115 million Series C financing round led by CTI Life Sciences Fund, funds managed by abrdn Inc., and Advent Life Sciences, alongside continued investment from existing investors, Novo Holdings, Sanofi Ventures, Abingworth, RiverVest Venture Partners, Sanderling Ventures, Chiesi Ventures, Remiges Ventures, and Asahi Kasei Ventures. Wilson Sonsini Goodrich & Rosati advised Glycomine on the transaction.
Client Highlights
4.07.25
Wilson Sonsini Advises RayThera on $110 Million Series A
On April 4, 2025, San Diego-based RayThera, Inc., a biotechnology company focused on small molecule therapies in immunology, announced the successful completion of a $110 million Series A round co-led by Foresite Capital and OrbiMed Advisors, with participation from TTM Capital. Wilson Sonsini Goodrich & Rosati advised RayThera on the transaction.
Client Highlights
4.02.25
Wilson Sonsini Advises Edgewise Therapeutics on $200 Million Underwritten Offering
On April 2, 2025, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an offering price of $20.13 per share. Edgewise anticipates gross proceeds from the offering to be approximately $200 million, before deducting underwriting discounts and commissions and offering expenses. The closing of the offering is expected to occur on April 3, 2025. Wilson Sonsini Goodrich & Rosati represented Edgewise Therapeutics on the transaction.
News Articles
8.08.24
IFLR1000 Recognizes Wilson Sonsini Practices, Attorneys in 2024 Guide
In the 2024 edition of its annual guide, IFLR recognized Wilson Sonsini practices and attorneys for their work in the financial and corporate sectors in the U.S. and China. The guide uses in-depth market analysis and interviews with practitioners and clients to determine leading financial and corporate law firms worldwide. Wilson Sonsini’s rankings are summarized below.
Client Highlights
2.28.24
Wilson Sonsini Advises Denali Therapeutics on $500 Million Private Placement Financing
On February 27, 2024, California-based Denali Therapeutics, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, announced that it has entered into a securities purchase agreement with certain existing accredited investors to issue and sell an aggregate of 3,244,689 shares of its common stock at a price of $17.07 per share and pre-funded warrants to purchase 26,046,065 shares of common stock at a purchase price of $17.06 per pre-funded warrant share, through a private investment in public equity (PIPE) financing. Denali Therapeutics anticipates gross proceeds from the PIPE to be approximately $500 million. Wilson Sonsini Goodrich & Rosati advised Denali Therapeutics on the transaction.